Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)-Reference-Cited by-同舟云学术

Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

Published:2023-06 Issue: Volume: Page:
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

De las Cuevas Carlos^ORCID,Sanz Emilio J.^ORCID,de Leon Jose^ORCID

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference62 articles.

1. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future;Alomar;Ther. Adv. Drug. Saf.,2020

2. International trends in clozapine use: a study in 17 countries;Bachmann;Acta Psychiatr. Scand.,2017

3. Using rich data on comorbidities in case-control study design with electronic health record data improves control of confounding in the detection of adverse drug reactions;Backenroth;PLoS One,2016

4. Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: focus on reports from various countries;De Las Cuevas;Rev. Psiquiatr. Salud Ment. (Engl Ed).,2022

5. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase;De Las Cuevas;Expert. Rev. Clin. Pharmacol.,2022

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature;Expert Opinion on Drug Safety;2024-09-11

2. Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia;Expert Opinion on Drug Metabolism & Toxicology;2024-07-02

3. When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis;CNS Drugs;2024-07-01

4. A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis;Clinical Psychopharmacology and Neuroscience;2024-06-07

5. Group arts therapies for patients with schizophrenia: a protocol of systematic review and meta-analysis;BMJ Open;2024-06